

Anchalee Avihingsanon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8723648/publications.pdf>

Version: 2024-02-01

71
papers

3,332
citations

430754

18
h-index

149623

56
g-index

72
all docs

72
docs citations

72
times ranked

5520
citing authors

#	ARTICLE	IF	CITATIONS
1	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , 2015, 373, 795-807.	13.9	2,232
2	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. <i>Hepatology</i> , 2008, 48, 1062-1069.	3.6	121
3	Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. <i>AIDS Research and Therapy</i> , 2015, 12, 12.	0.7	82
4	Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. <i>Lancet HIV</i> , 2016, 3, e410-e420.	2.1	73
5	CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV. <i>AIDS Research and Therapy</i> , 2018, 15, 13.	0.7	49
6	Cytomegalovirus Viremia in Thai HIV-Infected Patients on Antiretroviral Therapy: Prevalence and Associated Mortality. <i>Clinical Infectious Diseases</i> , 2013, 57, 147-155.	2.9	47
7	Influence of <i>ABCC2</i> and <i>ABCC4</i> Polymorphisms on Tenofovir Plasma Concentrations in Thai HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3240-3245.	1.4	43
8	Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1945-1955.	3.1	38
9	Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: prospective TB cohort from the Thailand Big City TB Research Network. <i>International Journal of Infectious Diseases</i> , 2017, 59, 96-102.	1.5	37
10	Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: Role of vitamin D levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1706-1714.	1.4	34
11	New-onset diabetes in HIV-treated adults. <i>Aids</i> , 2017, 31, 1535-1543.	1.0	34
12	Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 321-328.	0.9	34
13	Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 299-305.	0.6	32
14	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2017, 4, e486-e494.	2.1	31
15	Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection. <i>PLoS Pathogens</i> , 2020, 16, e1008744.	2.1	28
16	Diabetes mellitus burden among people living with HIV from the Asia-Pacific region. <i>Journal of the International AIDS Society</i> , 2019, 22, e25236.	1.2	25
17	Compulsory drug detention exposure is associated with not receiving antiretroviral treatment among people who inject drugs in Bangkok, Thailand: a cross-sectional study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2015, 10, 16.	1.0	23
18	Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection—Lessons for Functional HBV Cure?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 527-533.	0.9	20

#	ARTICLE	IF	CITATIONS
19	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 453-460.	1.1	19
20	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	2.9	19
21	Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. <i>International Journal of Infectious Diseases</i> , 2017, 61, 89-96.	1.5	17
22	Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e85-e92.	0.9	17
23	Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. <i>PLoS ONE</i> , 2016, 11, e0161562.	1.1	17
24	Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study. <i>PLoS ONE</i> , 2020, 15, e0230368.	1.1	16
25	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , 2018, 32, 985-997.	1.0	15
26	Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand. <i>Clinical Infectious Diseases</i> , 2017, 64, S171-S178.	2.9	14
27	Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross-Sectional Study. <i>PLoS ONE</i> , 2016, 11, e0154221.	1.1	13
28	Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 448-458.	3.7	13
29	Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. <i>Clinical Infectious Diseases</i> , 2015, 61, 633-639.	2.9	12
30	Natural Polymorphisms in <i>Mycobacterium tuberculosis</i> Conferring Resistance to Delamanid in Drug-Naive Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	12
31	Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. <i>Lancet HIV</i> , 2016, 3, e13-e22.	2.1	11
32	Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 933-938.	0.6	11
33	Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2317-2324.	2.9	10
34	The rate of bone loss slows after 2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy. <i>HIV Medicine</i> , 2020, 21, 64-70.	1.0	10
35	Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand. <i>Liver International</i> , 2020, 40, 2104-2109.	1.9	10
36	Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 327-332.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count $\leq 200\text{ cells/mm}^3$ in Thailand. <i>Journal of Virus Eradication</i> , 2020, 6, 100005.	0.3	7
38	HIV Coinfection Is Associated with Low-Fitness <i>rpoB</i> Variants in Rifampicin-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
39	Decline in Serum 25 Hydroxyvitamin D Levels in HIV-Hbv-Coinfected Patients after Long-Term Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2014, 19, 41-49.	0.6	6
40	Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV. <i>Journal of the International AIDS Society</i> , 2019, 22, e25264.	1.2	6
41	Early mortality after late initiation of antiretroviral therapy in the TREAT Asia HIV Observational Database (TAHOD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Asia-Pacific. <i>HIV Medicine</i> , 2020, 21, 397-402.	1.0	6
42	Pharmacogenetic Testing Can Identify Patients Taking Atazanavir at Risk for Hyperbilirubinemia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e36-e37.	0.9	5
43	Long-term loss to follow-up in the TREAT Asia HIV Observational Database (TAHOD). <i>HIV Medicine</i> , 2019, 20, 439-449.	1.0	5
44	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25494.	1.2	5
45	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. <i>HIV Research and Clinical Practice</i> , 2020, 21, 11-23.	1.1	5
46	Performance of a simple flow cytometric assay in diagnosing active tuberculosis. <i>Tuberculosis</i> , 2021, 126, 102017.	0.8	5
47	Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy. <i>Journal of the International AIDS Society</i> , 2022, 25, e25900.	1.2	5
48	Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 984-993.	0.6	4
49	Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2 binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. <i>Hepatology Research</i> , 2021, 51, 528-537.	1.8	4
50	Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. <i>Clinical Therapeutics</i> , 2020, 42, 1234-1245.	1.1	4
51	Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. <i>HIV Medicine</i> , 2022, 23, 274-286.	1.0	4
52	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD). <i>Journal of the International AIDS Society</i> , 2017, 20, e25016.	1.2	3
53	HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25736.	1.2	3
54	Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 949.	0.3	3

#	ARTICLE	IF	CITATIONS
55	A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients. <i>Journal of Virus Eradication</i> , 2016, 2, 22-7.	0.3	3
56	Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. <i>HIV Medicine</i> , 2022, 23, 959-968.	1.0	3
57	Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	3
58	Prevalence and Risks of Depression and Substance Use Among Adults Living with HIV in the Asia-Pacific Region. <i>AIDS and Behavior</i> , 2022, 26, 3862-3877.	1.4	3
59	Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection. <i>AIDS Research and Therapy</i> , 2013, 10, 21.	0.7	2
60	Response to Screening of diabetes mellitus among people living with HIV – a comment on “Diabetes mellitus burden among people living with HIV from the Asia-Pacific region” (Han et al. 2019). <i>Journal of the International AIDS Society</i> , 2019, 22, e25334.	1.2	2
61	Prevalence and the associated factors of hepatitis B and hepatitis C viral infections among HIV-positive individuals in same-day antiretroviral therapy initiation program in Bangkok, Thailand. <i>BMC Public Health</i> , 2022, 22, 144.	1.2	2
62	<sc>BMI</sc> as a predictor of high fasting blood glucose among people living with <sc>HIV</sc> in the Asia-Pacific region. <i>HIV Medicine</i> , 0, , .	1.0	1
63	The 16th Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 2013, 8, 331-333.	0.9	0
64	Mortality following diagnosis of tuberculosis in <sc>HIV</sc>-infected patients in Asia. <i>HIV Medicine</i> , 2018, 19, e70.	1.0	0
65	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 436-443.	0.9	0
66	Conference proceedings from the 22nd Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 2020, 15, 211-214.	0.9	0
67	Conference proceedings from the 23rd Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 2021, 16, 255-276.	0.9	0
68	Elimination of hepatitis C among HIV-positive population in Asia: old and new challenges. <i>Future Virology</i> , 2021, 16, 407-417.	0.9	0
69	Impact of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/ritonavir trough concentrations in Thai HIV-infected patients. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-14-6.	0.0	0
70	Conference proceedings from virtual 24th Bangkok International Symposium on HIV medicine. <i>Future Virology</i> , 0, , .	0.9	0
71	High Proportion of Blood-Borne and Sexually Transmitted Infections Among People Deprived of Liberty in a Central Male Prison in Thailand: A Cross-Sectional Study 2018-2019. <i>AIDS Research and Human Retroviruses</i> , 2022, , .	0.5	0